Segmed Partners With Verily to Expand Access to Biomedical Data Infrastructure

According to a recent LinkedIn post from Segmed, the company is partnering with Verily, part of Alphabet Inc., to broaden access to Verily Pre Exchange and Workbench through a new free self-serve Standard tier. The post indicates that this collaboration is intended to expand secure, compliant access to biomedical data infrastructure for the research community.

The company’s LinkedIn post highlights that Segmed is contributing longitudinal, real-world imaging data linked with structured clinical information to Verily’s ecosystem. The post suggests that these research-ready, de-identified datasets are aimed at supporting precision health, AI development, and translational research programs that may require regulatory-grade data quality.

From an investor perspective, this partnership may enhance Segmed’s visibility and integration within a larger, Alphabet-affiliated research platform, potentially increasing data usage and customer adoption over time. Association with Verily could strengthen Segmed’s positioning in the real-world data and healthcare AI infrastructure space, which may support future revenue opportunities and strategic relevance in biomedical research workflows.

The emphasis on secure, compliant, and rigorously prepared datasets suggests that Segmed is targeting segments of the market where regulatory and scientific standards are high. If the collaboration leads to broader uptake among academic, clinical, and industry researchers, Segmed could benefit from network effects within the Verily ecosystem and improved competitive differentiation against other real-world data providers.